← Leaderboards
Michal Mrug
Birmingham Va Medical Center
$2,765,657
Attributed
$2,765,657
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $496.4K · FY2013–25$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,765,657 · 3
VA$0 · 3
By mechanism
R01$1,598,444 · 1
P30$883,340 · 1
U54$283,873 · 1
I01$0 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Disease Progression”
- Lawrence Corey · Fred Hutchinson Cancer Center$405,086,239
- Constance Ann Benson · University Of California, San Diego$244,117,339
- Jeffrey P Krischer · University Of South Florida$225,151,653
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$150,116,206
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,027,526
Research focus
Disease ProgressionCellsPathway InteractionsPharmaceutical PreparationsKidneyComplementBaseAttenuatedResponseAutosomal Dominant Polycystic KidneyCystic KidneyPathogenesisPre-ClinicalCell LineEnd Stage Renal FailureDisease ModelIn VitroMutationMolecularDefectInnovationImmuneEpithelial CellsAffect
Grant awards (22)
Role of complement in injury-induced cystogenesis among carriers of a single ADPKD gene defect$0
I01 · FY2025 · VA · contact PI
Role of complement in injury-induced cystogenesis among carriers of a single ADPKD gene defect$0
I01 · FY2024 · VA · contact PI
Intra-renal T-cell heterogeneity in ADPKD patients$0
I01 · FY2023 · VA · contact PI
Intra-renal T-cell heterogeneity in ADPKD patients$0
I01 · FY2022 · VA · contact PI
UAB Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) - Therapeutic Development and Screening Resource$140,585
U54 · FY2021 · DK · contact PI
Intra-renal T-cell heterogeneity in ADPKD patients$0
I01 · FY2021 · VA · contact PI
UAB Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) - Therapeutic Development and Screening Resource$143,288
U54 · FY2020 · DK · contact PI
Intra-renal T-cell heterogeneity in ADPKD patients$0
I01 · FY2020 · VA · contact PI
The Hepato/Renal Fibrocystic Diseases Therapeutic and Screening Resource: Core D$176,668
P30 · FY2019 · DK · contact PI
The Hepato/Renal Fibrocystic Diseases Therapeutic and Screening Resource: Core D$176,668
P30 · FY2018 · DK · contact PI
Mechanisms of C3 effects in ARPKD pathogenesis$319,725
R01 · FY2017 · DK · contact PI
The Hepato/Renal Fibrocystic Diseases Therapeutic and Screening Resource: Core D$176,668
P30 · FY2017 · DK · contact PI
Pathobiology of Complement C3 effects in ADPKD$0
I01 · FY2017 · VA · contact PI
Mechanisms of C3 effects in ARPKD pathogenesis$319,725
R01 · FY2016 · DK · contact PI
The Hepato/Renal Fibrocystic Diseases Therapeutic and Screening Resource: Core D$176,668
P30 · FY2016 · DK · contact PI
Pathobiology of Complement C3 effects in ADPKD$0
I01 · FY2016 · VA · contact PI
Mechanisms of C3 effects in ARPKD pathogenesis$319,725
R01 · FY2015 · DK · contact PI
The Hepato/Renal Fibrocystic Diseases Therapeutic and Screening Resource: Core D$176,668
P30 · FY2015 · DK · contact PI
Pathobiology of Complement C3 effects in ADPKD$0
I01 · FY2015 · VA · contact PI
Mechanisms of C3 effects in ARPKD pathogenesis$319,725
R01 · FY2014 · DK · contact PI
Pathobiology of Complement C3 effects in ADPKD$0
I01 · FY2014 · VA · contact PI
Mechanisms of C3 effects in ARPKD pathogenesis$319,544
R01 · FY2013 · DK · contact PI